A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound.

Eli Lilly has once again delivered extraordinary financial results, powered by its highly successful diabetes and obesity treatments. The pharmaceutical giant's third-quarter performance has left ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, cheaper access nationwide.

The collaboration marks the first time patients using LillyDirect, Lilly’s direct-to-consumer healthcare platform can access self-pay pricing for Zepbound vials at a retail pharmacy location.

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...